Found 17 matching trials
Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer
PHASE3AMBRE is a phase III study comparing two standard treatments as initial met...
Status
Active Not Recruiting
Location
Centre Hospitalier Lyon Sud
Breast Cancer and Chemo-amennorhea
N/ARelation between chemotherapy and amennorhea...
Location
Clinique Saint Vincent
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
PHASE3In this clinical trial, the Sponsor plans to investigate whether patients w...
Location
Universitaetsklinikum Mannheim GmbH Frauenklinik
Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
N/ATo prospectively evaluate the impact of HER2DX on the decision-making proce...
Location
Istituto Europeo di Oncologia
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
PHASE3The main purpose of this study is to measure how well abemaciclib works in ...
Location
Palo Verde Cancer Specialists
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
PHASE2This trial is a multicenter, open-label, non-comparative, phase II, biomark...
Location
Complejo Hospitalario Universitario A Coruña (CHUAC)
Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
NAThe aim of CHRONO trial is to compare the DFS when surgery is performed aft...
Location
ICA - Polyclinique Urbain V
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
PHASE2ELOS is a prospective, randomized, open-label, controlled, two-armed parall...
Location
Universitätsklinikum Mannheim, Klinik für Hals-Nasen-Ohrenheilkunde Theodor-Kutzer-Ufer 1-3
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
PHASE2This was an open label, multi-center protocol for U.S. patients enrolled in...
Location
Arizona Oncology Associates PC- HAL
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
PHASE3The study investigates, whether the patient group with intermediate-risk ea...
Status
Active Not Recruiting
Location
Ost-Alb Klinikum Brustzentrum